Market Place
Sourcing Support
Affimed Reports Update on AFM24/Atezolizumab Combo for NSCLC
17 Dec 2024 //
GLOBENEWSWIRE
Affimed Hosts Investor Call on AFM24 & Atezolizumab in NSCLC
09 Dec 2024 //
GLOBENEWSWIRE
Affimed Reports Promising Phase 1 Data for AFM28 in R/R AML
09 Dec 2024 //
GLOBENEWSWIRE
Affimed: Acimtamig and AlloNK® Positive in Relapsed Hodgkin Lymphoma
08 Dec 2024 //
GLOBENEWSWIRE
Affimed`s Acimtamig & AlloNK® Granted RMAT Designation by FDA
05 Dec 2024 //
GLOBENEWSWIRE
Affimed Reports Q3 2024 Financial Results & Business Update
14 Nov 2024 //
GLOBENEWSWIRE
Affimed to Report Q3 2024 Financial Results & Corporate Update
06 Nov 2024 //
GLOBENEWSWIRE
Affimed Announces Three ASH Abstracts, Including Oral Presentation
05 Nov 2024 //
GLOBENEWSWIRE
Affimed To Present At Cantor Global Healthcare Conference 2024
10 Sep 2024 //
GLOBENEWSWIRE
Affimed Reports Second Quarter 2024 Financial Results
05 Sep 2024 //
GLOBENEWSWIRE
Affimed Appoints Shawn M. Leland as Chief Executive Officer
03 Sep 2024 //
GLOBENEWSWIRE
Affimed to Report Q2 2024 Financial Results and Corporate Update on September 5
29 Aug 2024 //
GLOBENEWSWIRE
Affimed Reports First Quarter 2024 Financial Results & Business Update
12 Jun 2024 //
GLOBENEWSWIRE
Affimed: Q1 2024 Financials & Corporate Update On June 12
05 Jun 2024 //
GLOBENEWSWIRE
Affimed`s AFM24 Combo Shows Durable Responses In Pretreated NSCLC
01 Jun 2024 //
GLOBENEWSWIRE
Affimed Gets Fast Track For AFM24-Atezolizumab In NSCLC
29 May 2024 //
GLOBENEWSWIRE
Affimed Announces Annual General Meeting of Shareholders
28 May 2024 //
GLOBENEWSWIRE
Affimed Early Efficacy Results: Afm24-102 Egfrwt Nsclc At Asco 2024
23 May 2024 //
GLOBENEWSWIRE
Affimed Announces AFM28 Preclinical Data Abstract At EHA 2024
14 May 2024 //
GLOBENEWSWIRE
Affimed`s AFM24 Abstract at ASCO 2024
24 Apr 2024 //
GLOBENEWSWIRE
Affimed Reports 2023 Financial Results and Operational Progress
28 Mar 2024 //
GLOBENEWSWIRE
Affimed Announces 1-for-10 Reverse Stock Split
06 Mar 2024 //
GLOBENEWSWIRE
Affimed Provides Clinical Response Update on AFM24-102 Trial
08 Jan 2024 //
GLOBENEWSWIRE
Affimed Announces Leadership Change and Organizational Restructuring
08 Jan 2024 //
GLOBENEWSWIRE
Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck
03 Jan 2024 //
GLOBENEWSWIRE
Affimed Announces Phase 1/2 Data from Acimtamig with Allogeneic NK in Lymphoma
11 Dec 2023 //
GLOBENEWSWIRE
Affimed Announces Positive Data for AFM24 in Combination with Atezolizumab
11 Dec 2023 //
GLOBENEWSWIRE
Affimed stops enrolling multiple tumor types as data disappoint
11 Dec 2023 //
FIERCE BIOTECH
Affimed to Report Third Quarter 2023 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13
02 Nov 2023 //
GLOBENEWSWIRE
Affimed to Participate in Upcoming Investor Conferences
01 Nov 2023 //
GLOBENEWSWIRE
Affimed Announces Listing Transfer to Nasdaq Capital Markets
04 Oct 2023 //
GLOBENEWSWIRE
Affimed Announces Acceptance of an Abstract Comparing NK Cells
27 Sep 2023 //
GLOBENEWSWIRE
Affimed to Present at the Cantor Global Healthcare Conference 2023
21 Sep 2023 //
GLOBENEWSWIRE
Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK
12 Sep 2023 //
GLOBENEWSWIRE
Affimed to Present at the H.C. Wainwright Annual Global Investment Conference
07 Sep 2023 //
GLOBENEWSWIRE
Affimed Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Affimed to Report Second Quarter 2023 Financial Results
03 Aug 2023 //
GLOBENEWSWIRE
Affimed Announces an ASCO Breakthrough Poster Presentation with Data of AFM24
31 Jul 2023 //
GLOBENEWSWIRE
ASCO: Affimed pivots to cancer combo as monotherapy falls short
05 Jun 2023 //
FIERCE BIOTECH
Affimed Presents AFM24 Monotherapy Data in Non-Small Cell Lung Cancer
03 Jun 2023 //
GLOBENEWSWIRE
Affimed to Present at the 2023 Jefferies Healthcare Conference
30 May 2023 //
GLOBENEWSWIRE
Affimed Announces Publication of AFM24 Clinical Abstracts for the Annual Meeting
25 May 2023 //
GLOBENEWSWIRE
Affimed reveals 25% of staff were let go in April
24 May 2023 //
FIERCE BIOTECH
Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13
23 May 2023 //
GLOBENEWSWIRE
Affimed Reports First Quarter 2023 Financial Results and Highlights Progress
23 May 2023 //
GLOBENEWSWIRE
Affimed Announces Annual General Meeting of Shareholders
22 May 2023 //
GLOBENEWSWIRE
Affimed to Report 1Q 2023 FYR & Corporate Update on May 23, 2023
16 May 2023 //
GLOBENEWSWIRE
Affimed Announces Abstracts at Meeting of the European Hematology Association
11 May 2023 //
GLOBENEWSWIRE
Affimed Announces AFM24 Clinical Abstracts Accepted for ASCO
26 Apr 2023 //
GLOBENEWSWIRE
Affimed Shares Preclinical Data on AFM13â Mechanism of Action Demonstrating
17 Apr 2023 //
GLOBENEWSWIRE
AACR: New Affimed data disappoints after Nasdaq flags stock dip
17 Apr 2023 //
FIERCE BIOTECH
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
06 Apr 2023 //
GLOBENEWSWIRE
Affimed Announces First Patient Dosed in the First-in-Human Study of AFM28
29 Mar 2023 //
GLOBENEWSWIRE
Affimed Reports 2022 Financial Results and Operational Progress
23 Mar 2023 //
GLOBENEWSWIRE
Affimed to Report Full Year 2022 Financial Results on March 23, 2023
16 Mar 2023 //
GLOBENEWSWIRE
Affimed Announces Presentations of Clinical Data from AFM13 Phase 2 REDIRECT
14 Mar 2023 //
GLOBENEWSWIRE
AbCheck Announces Completion of R&D Under Grant for Microfluidics Technology
09 Mar 2023 //
GLOBENEWSWIRE
Affimed to Participate in Fireside Chat at Wainwright Cell Therapy Conference
22 Feb 2023 //
GLOBENEWSWIRE
